论文部分内容阅读
本文报告了104例接受自体骨髓移植(ABMT)的非霍奇金淋巴瘤(NHL)患者,其中低度恶性9例,中度恶性31例,高度恶性64例。移植前属第1次完全缓解(CR_1)者46例,CR_2者14例,CR_3 7例,对化疗敏感者16例,化疗耐药者21例。全部患者按Kaplan-Meier生存曲线推算估计5年无病存活率(DFS)为49％[95％可信区间(CI)36％～63％],中数随访时间24月,在可供评价的80例患者中,5年时复发率为26％(95％CI14％～44％)。46例在CR_1时移植的患者,其8年DFS和复发率分别为75％(95％CI63％～82％)和15％(95％CI7％～33％),中数随访时间27月(13～104月),中数复发时间为
This article reports 104 non-Hodgkin lymphoma (NHL) patients who underwent autologous bone marrow transplantation (ABMT), of whom 9 were low-grade, 31 were moderate, and 64 were highly malignant. Before transplantation, there were 46 cases of first complete remission (CR_1), 14 cases of CR_2, 7 cases of CR_3, 16 cases of chemosensitivity and 21 cases of chemotherapy resistant. The 5-year disease-free survival (DFS) was 49% (95% confidence interval (CI) 36% -63%] based on Kaplan-Meier survival curves and was followed up for a median of 24 months in all eligible patients Among the 80 patients, the recurrence rate at 5 years was 26% (95% CI 14% to 44%). The 46-year DFS and relapse rate were 75% (95% CI63% -82%) and 15% (95% CI7% -33%) in 46 patients who were transplanted on CR_1. The median follow-up time was 27 months ~ 104 months), the median recurrence time is